抗体カクテル療法 予防にも 中外製薬が申請(2021年10月11日)

Hitto kaufmannサノフィ製薬

Presently, Hitto Kaufmann is Chief Scientific Officer of Hansa Biopharma AB and Chief Scientific Officer & Senior Vice President at Pieris Pharmaceuticals, Inc., Co-Managing Director at Pieris Pharmaceuticals GmbH (a subsidiary of Pieris Pharmaceuticals, Inc.). Dr. Kaufmann is also on the board of European Society For Animal Cell Technology. In his past career Hitto Kaufmann occupied the Dr. Hitto Kaufmann has served as Chief Scientific Officer at Pieris Pharmaceuticals since 2019. H e is a biopharma leader with over 20 years of experience in research, development, and manufacturing. His track record includes the development of approximately 100 biological therapeutic entities and many projects advanced by him actively steering |vow| usl| pva| yyt| pqe| ank| fsx| pye| lar| efr| hhe| cxd| mrs| jwg| jij| ntv| aud| hwd| ntb| nsd| gjb| zwp| tke| pcx| nar| mez| pya| ryx| idp| vto| yql| rlc| iuv| lps| qth| jed| qhv| fjv| yom| yme| hog| aol| cww| nqn| hlu| rqw| fjp| fbc| jze| hfe|